CHEK1 and systemic lupus erythematosus: Our ex vivo data revealed that in the course of an autoimmune response driven by type I IFN, ATR/Chk1 pathway was triggered and that targeted pharmaceutical inhibition of ATR activity restrained key features of SLE pathophysiology including B cell activation, plasmablast formation, antibody production, and proinflammatory cytokines release.